On January 6, 2022, Hoth Therapeutics, Inc. (began dosing to investigate the effect of HT-ALZ on memory, anxiety, and executive function in the APP/PS1+/- mice model after chronic dosing with HT-ALZ. In addition, on January 6, 2022 (the Effective Date), the Company extended the Non-Exclusive Commercial Evaluation License Agreement with Walter Reed Army Institute of Research, a subordinate laboratory of United States Army Medical Research and Materiel Command pursuant to which the term of the agreement was extended for a period of 18 months from the Effective Date.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.93 USD | +5.68% | +4.73% | -35.42% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-35.42% | 4.72M | |
+61.53% | 856B | |
+38.95% | 631B | |
-3.66% | 359B | |
+15.06% | 325B | |
+9.18% | 297B | |
+5.89% | 234B | |
+16.53% | 226B | |
+15.67% | 177B | |
+2.47% | 165B |
- Stock Market
- Equities
- HOTH Stock
- News Hoth Therapeutics, Inc.
- Hoth Therapeutics, Inc. Begins Dosing to Investigate the Effect of HT-ALZ on Memory, Anxiety, and Executive Function